Session Abstract – PMWC 2018 Silicon Valley
Session Synopsis: Multimodal molecular testing can now deliver a comprehensive overview of molecular disease. Drawing from experience across multiple platforms, more sensitive cost-effective testing is being developed to produce better diagnostic tools for a range of solid and hematological cancers.
Session Chair Profile
M.D., Chief Medical Officer and Director of Research and Development at NeoGenomics
Dr. Albitar, M.D., is formally trained in clinical pathology, hematopathology, and genetics. During his professional and academic tenure, he has published over 280 peer-reviewed publications and 10 books and book chapters focused on molecular characterization and diagnosis of cancer. He has served as Chief Medical Officer and Director of Research and Development at NeoGenomics since 2012. Prior to NeoGenomics, Dr. Albitar served as the Medical Director of Hematopathology and Oncology and Chief of R&D for Hematopathology and Oncology, Quest Diagnostics. He has held academic positions at The University of Texas MD Anderson Cancer Center as Full Professor in the Departments of Leukemia and Laboratory Medicine/Pathology and Director of Molecular Laboratory and Leukemia Section.
Ph.D., Technical Director of the NeoGenomics Molecular Laboratory at NeoGenomics
Dr. Funari, Ph.D., is formally trained in bioinformatics and genetics and is licensed as a clinical molecular biology and genetics scientist. During his professional and academic tenure, he has co-authored over 40 peer-reviewed publications in genomics. Currently, he is the Technical Director of the NeoGenomics Molecular Laboratory leading the clinical bioinformatics team to further develop molecular and genetic testing and offerings. Before joining NeoGenomics, he held faculty positions at the Medical Genetics Institute at Cedars-Sinai Medical Center and UCLA Medical Center. His expertise is the development of clinician-focused bioinformatics tools to analyze genomic data, next generation sequencing applications, and hematological oncology.